Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity Available to Purchase

PARP inhibitors (PARPi) are promising in BRCA2-altered prostate cancer. Data were presented on PARPi efficacy in prostate cancers with alterations in other DNA damage repair genes which suggest low response rates in ATM-, CHEK2-, CDK12-altered tumors and promising results in PALB2-, RAD51B-, FANCA-, and BRIP1-altered tumors.

See related article by Abida et al., p. 2487